GlassScriptPhysician profile
Seda Grigoryan
NPI 1881180511
$4,005.90
in general payments reported to CMS, 2019-2025
31 companies · $2,415 in 2025
The $2,415 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18.34 · 2023: $205 · 2024: $1,367 · 2025: $2,415.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,968 · Travel and Lodging: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,967.56 |
| Travel and Lodging | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $341.57 | 2024-2025 | Omnipod |
| Lilly USA, LLC | $314.02 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Cequr Corporation | $279.76 | 2024-2025 | Cequr Simplicity |
| Bayer Healthcare Pharmaceuticals INC. | $274.43 | 2024-2025 | |
| Novo Nordisk INC | $274.24 | 2024-2025 | Rybelsus, Ozempic |
| Corcept Therapeutics | $240.32 | 2024-2025 | Korlym |
| Sequel Med Tech, LLC | $226.24 | 2025 | Twiist |
| Medtronic, INC. | $204.70 | 2023 | Minimed 780g |
| Amgen INC. | $203.37 | 2025 | Tepezza, Repatha, Repatha |
| Abbvie INC. | $165.73 | 2024-2025 | |
| Amneal Pharmaceuticals LLC | $151.92 | 2024-2025 | Unithroid |
| Xeris Pharmaceuticals, INC. | $139.20 | 2024-2025 | Recorlev |
| Tandem Diabetes Care, INC. | $137.15 | 2024-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Sanofi-Aventis U.S. LLC | $125.07 | 2024 | |
| Dexcom, INC. | $124.80 | 2024-2025 | Dexcom G6 Transmitter |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $121.23 | 2025 | |
| Abbott Laboratories | $115.84 | 2024-2025 | Freestyle Libre 3 |
| Rgh Enterprises LLC | $109.07 | 2025 | |
| Ascendis Pharma Endocrinology INC | $99.18 | 2025 | Yorvipath |
| Mannkind Corporation | $50.62 | 2025 | |
| Antares Pharma, INC. | $49.60 | 2024-2025 | Xyosted |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.64 | 2024 | Jardiance |
| Alexion Pharmaceuticals, INC. | $35.25 | 2024-2025 | Strensiq |
| Lexicon Pharmaceuticals, INC. | $34.21 | 2024 | |
| Esperion Therapeutics, INC. | $32.36 | 2024-2025 | Nexletol |
| Alnylam Pharmaceuticals INC. | $27.67 | 2025 | Givlaari |
| Madrigal Pharmaceuticals | $20.96 | 2025 | Rezdiffra |
| Rhythm Pharmaceuticals, INC. | $20.77 | 2025 | Imcivree |
| Ultragenyx Pharmaceutical INC. | $18.34 | 2019 | |
| Acella Pharmaceuticals, LLC | $17.55 | 2025 | NP Thyroid 60 |
| Ibsa Pharma INC. | $15.09 | 2024 | Licart, Tirosint |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Seda Grigoryan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.